

**MALIGNANT HYPERTHERMIA ASSOCIATION
OF THE UNITED STATES, INC.**

FINANCIAL STATEMENTS

SEPTEMBER 30, 2005, 2004 AND 2003

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

TABLE OF CONTENTS

Statements of Financial Position	
September 30, 2005, 2004 and 2003	3
Statements of Activities	
For the years ended September 30, 2005, 2004 and 2003	4 - 5
Statements of Cash Flow	
For the years ended September 30, 2005, 2004 and 2003	7
Statement of Functional Expenses	
For the year ended September 30, 2005	8 - 9
Statements of Natural Expenses	
For the years ended September 30, 2005, 2004 and 2003	10
Notes to the Financial Statements	11 - 16
Supplementary Charts and Graphs	17 - 21

CWYNAR & COMPANY

Certified Public Accountants
A Professional Limited Liability Company
66 South Broad Street Suite 500 Norwich, NY 13815
Phone: (607) 334-3838 Fax: (607) 334-3837
Internet: Cwynar.com

Independent Auditors' Report

To the Board of Directors
Malignant Hyperthermia Association of the United States, Inc.
Sherburne, New York

We have audited the accompanying statements of financial position of Malignant Hyperthermia Association of the United States, Inc. as of September 30, 2005, 2004 and 2003, and the related statements of activities, functional expenses, and cash flow for the years then ended. These financial statements are the responsibility of the Organization's management. Our responsibility is to express an opinion on these financial statements based on our audit.

We conducted our audit in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audit provides a reasonable basis for our opinion.

In our opinion, the financial statements referred to above present fairly, in all material respects, the financial position of Malignant Hyperthermia Association of the United States, Inc. as of September 30, 2005, 2004 and 2003, and the changes in its net assets and its cash flows for the years then ended in conformity with generally accepted accounting principles.

The information included in the accompanying supplementary charts and graphs, referenced on the table of contents, is presented only for supplementary analysis purposes. Such information has been subjected to the auditing procedures applied in the audit of the financial statements and, in our opinion, is fairly stated, in all material respects, in relation to the financial statements taken as a whole.

Cwynar & Company

Norwich, New York
December 6, 2005

This page is intentionally left blank

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

STATEMENTS OF FINANCIAL POSITION

September 30,	2005	2004	2003
ASSETS			
Current assets			
Cash and equivalents	\$ 327,322	322,279	482,704
Investment in marketable securities	236,753	180,014	-
Pledges receivable, net	4,857	2,024	270
Inventories	45,201	49,985	71,800
Prepaid expenses	12,738	5,915	2,166
	626,871	560,217	556,940
Endowment Investments			
Cash and equivalents	128,811	124,098	134,767
Investment in marketable securities	20,502	15,940	-
	149,313	140,038	134,767
Fixed assets, net	13,682	16,173	11,263
	\$ 789,866	716,428	702,970
LIABILITIES			
Current liabilities			
Accounts payable	\$ 16,539	3,805	5,842
Accrued liabilities	3,655	4,427	3,834
	20,194	8,232	9,676
NET ASSETS			
Unrestricted	605,360	568,158	524,028
Temporarily restricted	34,121	15,665	49,183
Permanently restricted	130,191	124,373	120,083
	769,672	708,196	693,294
	\$ 789,866	716,428	702,970

See independent auditors' report

See accompanying notes to the financial statements

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

STATEMENTS OF ACTIVITIES

For the years ended September 30,	2005	2004	2003
UNRESTRICTED NET ASSETS			
Unrestricted Revenues and Gains			
Contributions			
General public	\$ 108,185	107,737	105,301
Program Service Fees			
General public	45,601	42,777	42,391
Business community	68,180	46,569	110,167
Investment Transactions			
Interest income	10,428	2,441	3,008
Dividend income	1,265	254	-
Unrealized gains (losses) on investments	3,783	548	-
Other gains (losses)	125	(172)	3,074
	237,567	200,154	263,941
Net assets released from donor restrictions	395,468	412,727	359,385
	633,035	612,881	623,326
Functional expenses			
Program services			
Education	255,156	227,499	238,422
Research & clinical	152,155	141,005	107,219
Patient	33,506	29,831	21,512
Neuroleptic Malignant Syndrome	54,501	82,327	44,092
	495,318	480,662	411,245
Supporting services			
General & Administrative	55,218	52,137	48,272
Fundraising	45,297	35,952	28,667
	100,515	88,089	76,939
Total Functional expenses	595,833	568,751	488,184
Change in unrestricted net assets	37,202	44,130	135,142
Beginning of the year	568,158	524,028	388,886
End of the year	\$ 605,360	568,158	524,028

See independent auditors' report

See accompanying notes to the financial statements

For the years ended September 30,	2005	2004	2003
TEMPORARILY RESTRICTED NET ASSETS			
Grants	\$ 66,450	65,500	39,700
Contributions	336,500	302,500	285,000
Contributions from general public	7,517	10,229	14,883
Interest income	3,030	980	1,232
Dividend income	107	-	-
Unrealized gains (losses) on investments	320	-	-
Net assets released from donor restrictions	(395,468)	(412,727)	(359,385)
Change in temporarily restricted net assts	18,456	(33,518)	(18,570)
Beginning of the year	15,665	49,183	67,753
End of the year	\$ 34,121	15,665	49,183

See independent auditors' report

See accompanying notes to the financial statements

For the years ended September 30,	2005	2004	2003
PERMANENTLY RESTRICTED NET ASSETS			
Contributions from general public	\$ 5,818	4,290	4,466
Net assets released from donor restrictions	-	-	-
Change in permanently restricted net assets	5,818	4,290	4,466
Beginning of the year	124,373	120,083	115,617
End of the year	\$ 130,191	124,373	120,083

See independent auditors' report

See accompanying notes to the financial statements

This page is intentionally left blank

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

STATEMENTS OF CASH FLOW

For the years ended September 30,	2005	2004	2003
Operating activities			
Change in net assets	\$ 61,476	14,902	121,038
Adjustments to reconcile change in net assets to net cash provided (used) by operating activities:			
Depreciation	5,642	4,886	5,426
Unrealized (Gain)Loss on marketable securities	(4,103)	(548)	-
(Gain)Loss on disposal of assets	-	225	-
Accounts receivable	(2,833)	(1,754)	45,317
Prepaid expenses	(6,823)	(3,749)	3,337
Inventories	4,783	21,815	1,976
Accounts payable	12,734	(2,037)	(15,996)
Accrued liabilities	(772)	593	140
	70,104	34,333	161,238
Investing Activities			
Purchase of equipment	(3,151)	(10,021)	(6,663)
Proceeds from sale of marketable securities	64,000	-	-
Purchase of marketable securities	(117,138)	(199,466)	-
Net change in endowment cash investments	(8,772)	14,729	(6,397)
	(65,061)	(194,758)	(13,060)
Net change in cash	5,043	(160,425)	148,178
Cash at the beginning of the year	322,279	482,704	334,526
Cash at the end of the year	\$ 327,322	322,279	482,704
Supplemental Cash Flow Disclosures			
Bank charges	\$ 423	508	39
Income taxes paid	-	-	-
Non-cash financing	-	-	-

See independent auditors' report

See accompanying notes to the financial statements

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

STATEMENTS OF FUNCTIONAL EXPENSES

For the year ended September 30,	Program Services				Total
	Education	Research & Clinical	Patient	Neuroleptic Malignant Syndrome	
Salaries & Wages	\$ 102,177	24,042	18,031	20,035	\$ 164,285
Payroll expenses	26,392	6,210	4,657	5,175	42,434
Copywriting	2,040	480	360	400	3,280
Materials	10,756	2,531	1,900	2,109	17,296
Telephone	3,069	722	542	602	4,935
Postage & Shipping	7,539	1,774	1,330	1,478	12,121
Insurance	1,000	-	-	1,000	2,000
Occupancy	-	-	-	-	-
Bank charges	423	-	-	-	423
Professional fees	8,188	-	-	660	8,848
Contracted services	18,867	4,439	3,329	3,699	30,334
Printing & Publications	24,107	4,318	3,238	3,598	35,261
Conferences & Meetings	25,054	4,480	-	3,734	33,268
Symposium	-	-	-	987	987
Awards & Honors	-	3,500	-	4,000	7,500
Research grants	-	99,500	-	-	99,500
Travel	24,867	-	-	6,891	31,758
Other	677	159	119	133	1,088
Depreciation	-	-	-	-	-
	\$ 255,156	152,155	33,506	54,501	\$ 495,318

See independent auditors' report

See accompanying notes to the financial statements

For the year ended September 30,	Supporting Services			2005
	General & Administrative	Fundraising	Total	
Salaries & Wages	\$ 14,024	22,038	\$ 36,062	\$ 200,347
Payroll expenses	3,622	5,692	9,314	51,748
Copywriting	280	440	720	4,000
Materials	1,476	2,320	3,796	21,092
Telephone	421	662	1,083	6,018
Postage & Shipping	1,035	1,626	2,661	14,782
Insurance	4,253	-	4,253	6,253
Occupancy	11,980	-	11,980	11,980
Bank charges	-	-	-	423
Professional fees	6,802	3,779	10,581	19,429
Contracted services	2,590	4,069	6,659	36,993
Printing & Publications	302	417	719	35,980
Conferences & Meetings	-	4,108	4,108	37,376
Symposium	-	-	-	987
Awards & Honors	-	-	-	7,500
Research grants	-	-	-	99,500
Travel	2,698	-	2,698	34,456
Other	93	146	239	1,327
Depreciation	5,642	-	5,642	5,642
	\$ 55,218	45,297	\$ 100,515	\$ 595,833

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

STATEMENTS OF NATURAL EXPENSES

For the years ended September 30,	2005	2004	2003
Salaries & Wages	\$ 200,347	168,522	158,202
Payroll expenses	51,748	38,912	34,101
Copywriting	4,000	8,400	8,500
Materials	21,092	18,572	30,549
Telephone	6,018	5,718	6,235
Postage & Shipping	14,782	21,344	17,541
Insurance	6,253	6,269	6,241
Occupancy	11,980	11,199	12,034
Bank charges	423	508	39
Professional fees	19,429	16,977	5,750
Contracted services	36,993	33,983	61,307
Printing & Publications	35,980	35,573	36,405
Conferences & Meetings	37,376	27,721	6,506
Symposium	987	17,252	6,870
Awards & Honors	7,500	8,713	7,000
Research grants	99,500	87,856	52,000
Travel	34,456	55,919	29,543
Other	1,327	426	3,935
Depreciation	5,642	4,886	5,426
	\$ 595,833	568,750	488,184

See independent auditors' report

See accompanying notes to the financial statements

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

NOTES TO THE FINANCIAL STATEMENTS

Note 1 NATURE OF ACTIVITIES AND SIGNIFICANT ACCOUNTING POLICIES

The Malignant Hyperthermia Association of the United States, Inc. (MHAUS or the Organization) is a not-for-profit corporation that was formed for the purpose of increasing the medical professions' and the general public's awareness and understanding of the syndrome, malignant hyperthermia (MH). MHAUS is dedicated to reducing the morbidity and mortality of MH by improving medical care related to MH, providing support information for patients and improving the scientific understanding and research related to MH. It performs these objectives by publishing newsletters and articles, hosting educational seminars, attending appropriate professional and public seminars to disseminate information about the syndrome and performing such other functions as required to increase the knowledge of the syndrome.

Basis of Presentation

The Organization reports information regarding its financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets.

Use of Estimates

Management uses estimates and assumptions in preparing financial statements. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosures of contingent liabilities, and the reported revenue and expenses.

Inventory

Consists of educational materials. Videotapes, audio tapes, brochures, pamphlets, etc. in inventory are stated at the lower of cost or market, cost being determined using the first-in, first-out (FIFO) method.

Investments

Investments are carried at fair value. Unrealized gains and losses, if any, are included in the change in net assets.

Securities Transactions

The Organization records securities transactions and recognizes related revenues on a trade date basis. Investment banking fees and expenses are recorded on an accrual basis.

Promises to Give

Contributions from the public are recognized when the donor makes an unconditional promise to give cash (or any other valuable asset) to the Organization. Contributions that are restricted by the donor are reported as increases in unrestricted net assets if the restrictions expire in the fiscal year in which the contributions are recognized. All other donor-restricted contributions are reported as increases in temporarily or permanently restricted net assets depending on the nature of the restrictions. When a restriction expires, temporarily restricted net assets are reclassified to unrestricted net assets.

The Organization uses the allowance method to determine collectible unconditional promises receivable. The allowance is based on prior years' experience and management's analysis of specific promises made.

At the balance sheet date, there are no significant promises to give.

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

NOTES TO THE FINANCIAL STATEMENTS

Cash and Cash Equivalents

The Organization considers cash in operating bank accounts, cash on hand, and certificates of deposit, U.S. Treasury Bills and other highly liquid debt instruments purchased with maturity of three months or less to be cash and cash equivalents.

Pledges Receivable

The Organization uses the allowance for doubtful accounts method for valuing accounts receivable. This reduces the current balance of pledges receivable by the estimated bad debts expected to occur based on previous experience.

Property and Equipment

The Organization capitalizes all expenditures for land and land improvements, buildings, and equipment costing \$500 or more at cost. Depreciation is provided using the straight-line method over the estimated useful lives of the assets as follows:

Equipment and furniture	2-10 years
-------------------------	------------

Contributions of cash that must be used to acquire property and equipment are reported as temporarily restricted support. If the donor does not stipulate how long those assets must be maintained, the Organization reports expirations of donor restrictions when the acquired assets are placed in service as instructed by the donor. The Organization reclassifies temporarily restricted net assets to unrestricted net assets at that time.

Restricted and Unrestricted Revenue and Support

Contributions received are recorded as unrestricted, temporarily restricted, or permanently restricted support, depending on the existence and/or nature of any donor restrictions.

Support that is restricted by the donor is reported as an increase in temporarily or permanently restricted net assets, depending on the nature of the restriction. When a restriction expires (that is, when a stipulated time restriction ends or purpose restriction is accomplished), temporarily restricted net assets are reclassified to unrestricted net assets and reported in the Statement of Activities as net assets released from restrictions.

Donated Materials and Services

Donated materials are recorded as contributions at their estimated fair values at the date of donation. Contribution of services are recognized in the financial statements if the services enhance or create non-financial assets or require specialized skills, are provided by individuals possessing those skills, and would typically need to be purchased if not provided. No amounts have been reflected in the financial statements for those services.

Advertising

Advertising costs are generally charged to operations as incurred.

Income Taxes

MHAUS has been granted tax-exempt status under Section 501(c)(3) of the Internal Revenue Code.

Financial Statement Presentation

Certain amounts from the prior years' financial statements have been reclassified to conform to the current year presentation.

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

NOTES TO THE FINANCIAL STATEMENTS

Functional Classification of Expenses

Functional expenses are charged to each program based on direct expenditures incurred. Any program expenditures not directly chargeable are allocated to a program based on units of service and support costs are allocated to a program based on total program costs. Salaries and related expenses are allocated to the various program and supporting services based on actual or estimated time employees spend on each function.

Education

The Malignant Hyperthermia Association of the United States, Inc provides a variety of educational support services for medical professionals and patients susceptible to malignant hyperthermia. These include videos, audio tapes, literature, monographs, professional conferences, special meetings, Web site, and newsletters.

Research & Clinical

This includes all activities that support the Malignant Hyperthermia Hotline, North American Malignant Hyperthermia Registry of MHAUS (located at the University of Pittsburgh Medical School, Pennsylvania) and research programs.

Patient

This includes programs directed to educate and support Malignant Hyperthermia Susceptible (MHS) patients and their families. The programs include all the materials mentioned under the education section but with the expansion emphasis on a patient educational conference and seminars, a patient identification tag program, a patient news bulletin and a patient liaison committee program where MHS patients work together to provide local and national support.

Neuroleptic Malignant Syndrome (NMS)

This category includes formation of a NMS hotline, educational support services and a database for medical professionals and patients' involvement in this syndrome caused by antipsychotic drugs.

General & Administrative

Expenditures associated with the overall operation of the Organization. These expenditures are not directly part of the program services operating at the Organization. They are indirect and necessary for the Organization's existence.

Fundraising

Expenditures associated with fundraising activities of the Organization. These expenditures are not directly part of the program services operating at the Organization.

Compensated Absences and Employee Benefits

Employees of the Organization are entitled to paid vacations, sick days, and personal days off, depending on job classification, length of service, and other factors.

There are no unfunded health care or retirement plans.

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

NOTES TO THE FINANCIAL STATEMENTS

Note 2 RESTRICTIONS ON NET ASSETS

The Organization's unrestricted net assets:

September 30,	2005
Designated for property and equipment	\$ 13,682
Undesignated	591,678
Unrestricted net assets	\$ 605,360

Restricted net assets are available for the following purposes or periods:

September 30, 2005	Permanent	Temporary	Total
Lila and Jerry Lewis Memorial Fund	\$ 71,547	11,456	\$ 83,003
Rosenberg Research Fund	42,679	6,493	49,172
Shah Educational Awareness Fund	15,965	1,172	17,137
Vanguard Anesthesia Associates Grant	-	5,000	5,000
Janssen Medical Affairs, LLC Grant	-	10,000	10,000
	\$ 130,191	34,121	\$ 164,312

Net assets were released from donor restrictions by incurring expenses satisfying the restricted purposes or by occurrence of other events specified by donors as follows:

September 30, 2005	Permanent	Temporary	Total
Procter & Gamble Pharmaceuticals	\$ -	336,500	\$ 336,500
American Society of Anesthesiologists	-	17,500	17,500
American Association of Nurse Anesthetists	-	4,950	4,950
Sharn	-	3,000	3,000
Vanguard Anesthesia Associates	-	5,000	5,000
Daniel Massik Memorial Fund	-	4,000	4,000
Janssen Medical Affairs, LLC	-	10,000	10,000
AstraZeneca LP	-	10,000	10,000
Pfizer, Inc.	-	2,000	2,000
Napolitano Fund	-	135	135
Neuroleptic Malignant Syndrome Donors	-	2,383	2,383
	\$ -	395,468	\$ 395,468

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

NOTES TO THE FINANCIAL STATEMENTS

Note 3 ENDOWMENT FUNDS AND TRUSTS

LILA & JERRY LEWIS MEMORIAL FUND

During fiscal 1987, the Organization became the recipient of this memorial fund. Use of monies contributed to this fund and any earnings are restricted for use in special programs, as designated and approved by the Board of Directors. The programs increase the general understanding of malignant hyperthermia. The fund is further restricted in that the Board may not use more than 20% of the corpus in any one fiscal year for such programs. It may, however, use any and all of the earnings from the fund for these programs.

ROSENBERG RESEARCH FUND

During fiscal 1995, the Organization became the recipient of this research fund. Use of monies contributed to this fund and any earnings are restricted for use in support of any type of research related to malignant hyperthermia or allied syndromes. The Board of Directors has ultimate authority on the use of the funds. However, the fund is further restricted in that the Board may not use more than 20% of the corpus at any one time. It may, however, use any and all of the earnings from the fund for these purposes.

SHAH EDUCATIONAL AWARENESS FUND

During fiscal 2000, the Organization established this fund. The purpose of the fund is to alert and educate medical professionals, assist patients, and disseminate new knowledge about Neuroleptic Malignant Syndrome. NMSIS will use publications, educational brochures, conferences and other methods for increasing awareness and ensuring that patients with NMS are recognized and treated efficiently and effectively. The Board of Directors has ultimate authority on the use of the funds.

Note 4 INVESTMENTS IN MARKETABLE SECURITIES

A Board of Directors governs the Organization's investment policies. The Organization has entered into an investment management agreement with a local financial institution in order to maximize return on their idle cash.

Investments in marketable securities with readily determinable fair values and all investments in debt securities are reported at their fair values in the statement of financial position. Unrealized gains and losses are included in the change in net assets.

Investments in marketable securities are summarized as follows:

September 30, 2005	Cost	Market	Unrealized Gain(Loss)
Domestic Equity Securities	\$ 46,547	\$ 52,988	\$ 6,441
Mutual Funds	6,037	6,553	516
Fixed Income Securities	200,020	197,714	(2,306)
	<u>\$ 252,604</u>	<u>\$ 257,255</u>	<u>\$ 4,651</u>

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

NOTES TO THE FINANCIAL STATEMENTS

The investments are sold when cash needs develop or when good investment management dictates a change in the securities held. The difference between the net proceeds from sale and cost represents the realized gain or loss on the sale of securities. The unrealized gain or loss for a year is the relative change in the market values from the beginning to the end of the year for securities that were not sold.

For the years ended September 30,	2005	2004
Capital Gains		
Unrealized gains (loss)	\$ 4,103	548
Interest earned		
Fixed income securities	4,726	18
Government obligations	7,034	3,403
Insurance company CD	1,698	-
Dividends		
Equities	1,372	254
	\$ 18,933	4,223

The Organization may, at times throughout the year, maintain certain bank accounts in excess of the FDIC insured limits.

Note 5 POST EMPLOYMENT EMPLOYEE BENEFITS

The Organization currently has no retirement plan or post employment benefit package.

Note 6 ECONOMIC DEPENDENCY

A major part of the Organization's contributions come from Procter & Gamble. Procter & Gamble's Pharmaceuticals division produces the drug, dantrolene sodium (Dantrium). Dantrium has been found to be a fast acting, effective treatment of malignant hyperthermia. A loss of the Procter & Gamble contribution would have a materially adverse effect on the Organization.

**MALIGNANT HYPERTHERMIA ASSOCIATION
OF THE UNITED STATES, INC.**

**SUPPLEMENTARY CHARTS AND GRAPHS
FOR THE YEAR ENDED SEPTEMBER 30, 2005**

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

SUPPLEMENTARY CHARTS AND GRAPHS

Figure 1




Figure 1 represents a percentage analysis of investments by the type of investment held.

Prior to the fiscal year ending 2004, nearly all investments held were government obligations. At the end of the 2004 fiscal year, the investments portfolio began to expand to include other types of securities. In 2005, additional amounts were invested in stocks, mutual funds, and certificates of deposit.

The diversification of investments has had a positive effect on the income earned from investing activities. Income earned on investments (including unrealized gains and losses) in the current year was \$18,933 compared to \$4,223 in the previous year.

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

SUPPLEMENTARY CHARTS AND GRAPHS

Figure 2




Figure 2 provides a comparison of support versus expenses over a three year period.

After experiencing a 4% drop in 2004, support increased 12% in 2005. The increase in current year support can be attributed to more program service fees received from the business community, an increase in the P&G grant, and income earned on investments.

Expenses increased 16% in 2004 and rose another 4% in 2005. The most significant increase comes from labor and benefit costs rising 21% in the current year. Labor and benefit costs were higher due to health insurance rate increases, turning a part-time position into a full-time position, and pay rate increases. Awarding of research grants increased 13% in the current year. Grants awarded in the current year accounted for nearly \$100,000, or 17% of total expenses.

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

SUPPLEMENTARY CHARTS AND GRAPHS

Figure 3




Figure 3 breaks down total expenses into natural expense categories.

Labor and benefits always account for the majority of expenses in this type of service organization. Historically, labor and benefits accounted for 37% of total expenses. Grants and awards have been rising steadily over the years as support continues to increase. Grants and awards have historically been closer to 10% of total expenses.

Conference and meeting expenses are lower than last year due to travel expenses dropping significantly. In the previous year, conferences and meetings expenses were 15% of total expenses.

MALIGNANT HYPERTHERMIA ASSOCIATION OF THE UNITED STATES, INC.

SUPPLEMENTARY CHARTS AND GRAPHS

Figure 4




Figure 4 shows expenses as classified by the function or program being served. Functional expenses are a reorganization of natural expenses.

Compared to last year, most functional expenses remained at nearly the same percentages. Education expenses increased as more was spent on the production of educational materials and publications.

In the previous year, Neuroleptic Malignant Syndrome (NMS) program expenses constituted 14% of total expenses as compared to 9% in the current year. The decrease in NMS expenses can be explained by the decrease in symposium expenses. Last year more than \$17,000 was spent on an educational symposium related to NMS. Symposium expenses were less than \$1,000 in the current year.

Functional expenses will fluctuate as the organization focuses resources in different areas from year to year. The types of events and activities held each year will dictate which programs see increased or decreased spending.